Compass Therapeutics (CMPX) Cash & Equivalents (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Cash & Equivalents data on file, last reported at $55.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 34.4% year-over-year to $55.2 million; the trailing twelve-month figure through Mar 2026 stood at $55.2 million (up 34.4% YoY), and the FY2025 full-year result was $31.2 million, down 29.15% from the prior year.
• Cash & Equivalents grew to $55.2 million in Q1 2026, from $31.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $136.4 million in Q1 2022 to a low of $16.5 million in Q3 2022.
• A 5-year average of $36.4 million and a median of $27.0 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 243.57% in 2022 and tumbled 80.18% in 2023, its largest moves.
• Tracing CMPX's Cash & Equivalents over 5 years: stood at $34.9 million in 2022, then slumped by 30.58% to $24.2 million in 2023, then surged by 81.82% to $44.1 million in 2024, then retreated by 29.15% to $31.2 million in 2025, then jumped by 76.76% to $55.2 million in 2026.
• Business Quant data shows CMPX's Cash & Equivalents at $55.2 million in Q1 2026, $31.2 million in Q4 2025, and $46.2 million in Q3 2025.